Replies to post #78377 on Amarin Corp Plc (AMRN)

[Invest83838]

Thank You Sam!


Your values are the ones that count since they are real instead of hypothetical and speculative.

Vascepa sales looking pretty good but they need to start being exponential in the near future to ward off future share dilution.

[ziploc_1]

SAM:....Thanx for your revealing graphs. They illustrate that Vascepa's main competition is generic Lovaza, with which it must narrow the gap in sales. Many Docs are still unaware of the superiority of V over Lovaza. The task for Amarin is to educate Docs on this difference. This will be the case even after R-IT demonstrates "overwhelming efficacy"... but the task will be made much easier and quicker.
Since Vascepa works over time to reduce CVE, testimonials of "how I took this pill and everything improved" will be less convincing than the scientific evidence radiating from R-IT. Lovaza is almost out of business. R-IT will put generic L out of business. The market for EPA is already there. Soon it will be up to Amarin to grow it.

[sts66]

Muchas gracias Sam - you da man! Will be very interesting to see whether the recent change in slope returns to the prior trend or continues on a new slope - the most recent data point is just about back to the old linear trend line. Market share (last plot) shows a clear break in previous trend, have already had an inflection in that line (acceleration).